Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheldon E Litwin

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
JAMA|September 20, 2012
Health benefits of gastric bypass surgery after 6 yearsTed D Adams, Lance E Davidson, Sheldon E Litwin, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
Plos Biology|November 9, 2006
Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performanceChristopher J Lelliott, Gema Medina-Gomez, Natasa Petrovic, et al.
European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Obesity (Silver Spring, Md.)|June 6, 2009
Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obeseTed D Adams, Robert C Pendleton, Michael B Strong, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
JAMA Cardiology|October 2, 2024
Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical TrialMarat Fudim, Barry A Borlaug, Rajeev C Mohan, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
JAMA|September 20, 2012
Health benefits of gastric bypass surgery after 6 yearsTed D Adams, Lance E Davidson, Sheldon E Litwin, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
Plos Biology|November 9, 2006
Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performanceChristopher J Lelliott, Gema Medina-Gomez, Natasa Petrovic, et al.
European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Obesity (Silver Spring, Md.)|June 6, 2009
Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obeseTed D Adams, Robert C Pendleton, Michael B Strong, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
JAMA Cardiology|October 2, 2024
Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical TrialMarat Fudim, Barry A Borlaug, Rajeev C Mohan, et al.
Pageof 18